Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia

<b>Background:</b> The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for patients with chemotherapy-induce...

Full description

Saved in:
Bibliographic Details
Main Authors: Advani S, Achreckar Suvarna, Thomas Dennis, Krishnankutty Binny
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2010-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2010;volume=31;issue=3;spage=125;epage=128;aulast=Advani
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849727929961938944
author Advani S
Achreckar Suvarna
Thomas Dennis
Krishnankutty Binny
author_facet Advani S
Achreckar Suvarna
Thomas Dennis
Krishnankutty Binny
author_sort Advani S
collection DOAJ
description <b>Background:</b> The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for patients with chemotherapy-induced febrile neutropenia (FN), we conducted an open, non-randomized clinical trial. <b>Materials and Methods:</b> This was a prospective, open, Phase IV clinical trial in patients receiving chemotherapy for histologically confirmed cancer, with an oral temperature of &gt;38.2&#176;C and absolute neutrophil count (ANC) of &lt;500/mm <sup>3</sup> . Filgrastim was administered subcutaneously in a dose of 5 mcg/kg/day, 24 hours after administration of cytotoxic therapy, for up to two weeks or until the ANC reached 10,000 cells/mm <sup>3</sup> . The parameters of assessment included duration of neutropenia, fever, hospitalization and antibiotic usage. <b>Results:</b> All 24 evaluable patients recovered from neutropenia, fever and FN in a median duration of two days. This result is similar to that reported in earlier studies with filgrastim. Despite the acceleration in recovery from neutropenia and fever, it also reduced the duration of hospital stay and usage of intravenous (IV) antibiotic. Only two adverse events were reported, which were of mild nature. <b>Conclusion:</b> Filgrastim, when used in patients with chemotherapy-induced neutropenia, exhibited efficacy in accelerating the recovery from neutropenia and fever comparable to that reported with filgrastim in literature. The data from this study suggest that filgrastim is effective in the treatment of chemotherapy-induced neutropenia and is well tolerated by Indian patients.
format Article
id doaj-art-7b4c8f157855487bb6ca3cfd8bd09ca1
institution DOAJ
issn 0971-5851
0975-2129
language English
publishDate 2010-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series Indian Journal of Medical and Paediatric Oncology
spelling doaj-art-7b4c8f157855487bb6ca3cfd8bd09ca12025-08-20T03:09:44ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292010-01-01313125128Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropeniaAdvani SAchreckar SuvarnaThomas DennisKrishnankutty Binny<b>Background:</b> The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for patients with chemotherapy-induced febrile neutropenia (FN), we conducted an open, non-randomized clinical trial. <b>Materials and Methods:</b> This was a prospective, open, Phase IV clinical trial in patients receiving chemotherapy for histologically confirmed cancer, with an oral temperature of &gt;38.2&#176;C and absolute neutrophil count (ANC) of &lt;500/mm <sup>3</sup> . Filgrastim was administered subcutaneously in a dose of 5 mcg/kg/day, 24 hours after administration of cytotoxic therapy, for up to two weeks or until the ANC reached 10,000 cells/mm <sup>3</sup> . The parameters of assessment included duration of neutropenia, fever, hospitalization and antibiotic usage. <b>Results:</b> All 24 evaluable patients recovered from neutropenia, fever and FN in a median duration of two days. This result is similar to that reported in earlier studies with filgrastim. Despite the acceleration in recovery from neutropenia and fever, it also reduced the duration of hospital stay and usage of intravenous (IV) antibiotic. Only two adverse events were reported, which were of mild nature. <b>Conclusion:</b> Filgrastim, when used in patients with chemotherapy-induced neutropenia, exhibited efficacy in accelerating the recovery from neutropenia and fever comparable to that reported with filgrastim in literature. The data from this study suggest that filgrastim is effective in the treatment of chemotherapy-induced neutropenia and is well tolerated by Indian patients.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2010;volume=31;issue=3;spage=125;epage=128;aulast=AdvaniFebrile neutropeniafilgrastimgranulocyte colony-stimulating factor
spellingShingle Advani S
Achreckar Suvarna
Thomas Dennis
Krishnankutty Binny
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Indian Journal of Medical and Paediatric Oncology
Febrile neutropenia
filgrastim
granulocyte colony-stimulating factor
title Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
title_full Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
title_fullStr Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
title_full_unstemmed Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
title_short Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
title_sort granulocyte colony stimulating factor filgrastim in chemotherapy induced febrile neutropenia
topic Febrile neutropenia
filgrastim
granulocyte colony-stimulating factor
url http://www.ijmpo.org/article.asp?issn=0971-5851;year=2010;volume=31;issue=3;spage=125;epage=128;aulast=Advani
work_keys_str_mv AT advanis granulocytecolonystimulatingfactorfilgrastiminchemotherapyinducedfebrileneutropenia
AT achreckarsuvarna granulocytecolonystimulatingfactorfilgrastiminchemotherapyinducedfebrileneutropenia
AT thomasdennis granulocytecolonystimulatingfactorfilgrastiminchemotherapyinducedfebrileneutropenia
AT krishnankuttybinny granulocytecolonystimulatingfactorfilgrastiminchemotherapyinducedfebrileneutropenia